Navigation Links
Knowing Heart Risk Keeps Patients on Cholesterol Drugs
Date:11/29/2007

In study, users were informed of their odds for cardiovascular disease

THURSDAY, Nov. 29 (HealthDay News) -- Letting patients know how cholesterol boosts their heart risks helps them stick to cholesterol-lowering treatment, Canadian researchers report.

Researchers at McGill University in Montreal enrolled more than 3,000 patients (2,687 completed the study) with cholesterol problems who were instructed to change their lifestyle and then prescribed cholesterol-lowering statin medications when necessary.

Of those patients, more than 1,500 were given a one-page computer printout of their probability for developing heart disease at the start of the study, and at follow-up visits three, six, nine and 12 months later.

At the end of the 12-month study, patients who'd received the heart disease risk profiles had small but significantly greater reductions in "bad" low-density lipoprotein (LDL) cholesterol levels and their ratio of total cholesterol to "good" high-density lipoprotein (HDL) cholesterol levels, the researchers said.

"Patients in the risk profile group were also more likely to reach lipid targets," the study authors wrote in the Nov. 26 issue of the journal Archives of Internal Medicine.

"Communicating risk (of heart disease) is consistent with many of the recommendations to improve adherence, including enhancing self-monitoring and using the support of family and friends," the researchers concluded.

"Informing patients of their coronary risk may also increase the effectiveness of primary prevention by identifying individuals most likely to benefit from treatment while reassuring those at low risk. This information may also assist physicians in treatment selection while improving patient adherence," the research team wrote.

The study was funded by Pfizer Inc., which makes the cholesterol-lowering drug Lipitor. The authors have associations with a number of drug makers.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. Restricting Blood Flow May Help Heart Bypass Patients
4. Urban Smog Tough on Young Adults Hearts
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Vitamin Es lack of heart benefit linked to dosage
7. Drug That Lowers Resting Heart Rate Being Tested
8. Heart Attack Boosts Diabetes Risk
9. Embryonic Stem Cells Repair Human Heart
10. U of M study: Early treatment can reverse heart damage
11. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ed Banzel proved effective against Lennox-Gastaut ...News) -- A new drug called Banzel (rufinamide) has...severe form of epilepsy called Lennox-Gastaut synd...ced Friday. , The approval was based on results...ents ages 4 to 30. Compared to patients who took a...
(Date:11/21/2008)...holders Intend To Vigorously Protect Investment An... Nov. 21 Dr. Stephen Jo...mendment to their Schedule 13D with the U.S. Secur...ly filed a 13D disclosing ownership of 11.4% of LC...7 LasikPlus fixed-site laser vision correction cen...
(Date:11/21/2008)... 2 popular drugs do not cause genetic damage that ...(HealthDay News) -- Two popular medications for tr...DHD) do not cause genetic damage linked to an incr.... , The study, done by researchers at Duke Univ...of Health, counters a previous one that reported b...
(Date:11/21/2008)...E, N.Y., Nov. 21 A prestigious gro...oviders will gather in Williamsburg, VA on March 2...tical, clinical information on cutting-edge therap...innovative research advances that impact patient c... registration information is available at www.bio...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2
...d out the increasing problem of super bugs to the ... farmlands. Super bugs are a new kind of microorga... affected by a wide range of antibiotics. The rese...ional Center and others who together had published...
...e treatment of osteoporosis is useful, but changes...tion. Nowadays the main treatment options are anti...r patients with previous fractures, treatment with...formation is preferable, and this is now possible ...
...July edition of the Journal of Neurosurgery sugges...everity of cases of constriction of blood vessels ...id haemorrhage (SAH). Normally constriction of b...following a SAH and this leads to strokes and neur...
...n chronic obstructive pulmonary disease (COPD) sai...en useful for patients of this disease to have imp...ructive pulmonary disease (COPD) are lung diseases...itions like lung tissue destruction, airway inflam...
Other Medicine News:Health News:The Benefits of Strontium in the treatment for Osteoporosis Questioned 2Health News:Clazosentan May help to Improve Blood Circulation after Brain Hemorrhage due to burst Aneurysm 2
(Date:11/19/2008)...ritical enzyme,s regulation may hold key to unders..., , MEMPHIS, Tenn., Nov. 19 /PRNewswire-USN...earch Hospital have gained new insights into regul...d calpains. , , As the cell,s molecular ov...ocesses, including the movement of cells in tissue...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
(Date:11/13/2008)...all/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leading ...agnostics, medical imaging systems and surgical pr...f women, today announced the results of the,Cervis...sta HPV high-risk,test is currently under review b...ed in the European Union (EU) early in 2009. The c...
(Date:11/12/2008)...12 Surgeons,at the University of R...-specific CTA data can be converted to an endovasc...th high face validity. The surgeons,"strongly agre...w,increased patient safety and efficiency of inst...scopy time and the amount of contrast used, and,th...
Breaking Medicine Technology:New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Raven biotechnologies inc and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2089 1Raven biotechnologies inc and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2089 2BioCryst Provides Forodesine HCl Update 994 1BioCryst Provides Forodesine HCl Update 994 2BioCryst Provides Forodesine HCl Update 994 3BioCryst Provides Forodesine HCl Update 994 4BioCryst Provides Forodesine HCl Update 994 5Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 1Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy 28TM 29 992 4This is your brain on violent media 7728 1This is your brain on violent media 7728 2
...ta Presented at the American Academy of Neurology ...tion in Partial Seizures, BOSTON, May 01, 2007 /PR...ed today at the American Academy of Neurology (AAN...ly extended release,formulation of Lamictal(R) (la...ients with partial epilepsy with and without,secon...
...Study of over 7,700 women published today shows re...rcent in hip fractures, EAST HANOVER, N.J., May 02...Reclast(R) (zoledronic acid) Injection significant...tic bone fractures,over three years in women with ... today in The New England Journal of Medicine,mar...
Other Medicine Technology:New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 2New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 3New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 4New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6
ACL 1000 is an affordable solution for low volume workloads, or as a backup analyzer. The test menu includes a variety of clotting assays, such as Lupus and APCR-V Leiden. The ACL 1000 also offers ba
The SYNCHRON CX4-S system consolidates DATs, TDMs and other esoteric tests in one workstation, targeted to the mid-size lab that processes 50-200 samples per day. Like all SYNCHRON CX super systems,
It takes powerful technology to increase laboratory efficiency and worker safety, and still lower costs. It takes the new SYNCHRON LX20 PRO, offering features that you will not find on any other chem
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance.
Medicine Products: